Dreyling M, European Mantle Cell Lymphoma Network. Mantle cell lymphoma: biology, clinical presentation, and therapeutic approaches. Am Soc Clin Oncol Educ Book Am Soc Clin Oncol Annu Meet. 2014:191–8.

Jain P, Wang ML. Mantle cell lymphoma in 2022-A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments. Am J Hematol. 2022;97:638–56.

CAS  PubMed  Article  Google Scholar 

Navarro A, Beà S, Jares P, Campo E. Molecular pathogenesis of mantle cell lymphoma. Hematol Oncol Clin North Am. 2020;34:795–807.

PubMed  PubMed Central  Article  Google Scholar 

Gerson JN, Handorf E, Villa D, Gerrie AS, Chapani P, Li S, et al. Survival outcomes of younger patients with mantle cell lymphoma treated in the rituximab era. J Clin Oncol Off J Am Soc Clin Oncol. 2019;37:471–80.

CAS  Article  Google Scholar 

Le Gouill S, Thieblemont C, Oberic L, Moreau A, Bouabdallah K, Dartigeas C, et al. Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma. N Engl J Med. 2017;377:1250–60.

PubMed  Article  Google Scholar 

Hoster E, Dreyling M, Klapper W, Gisselbrecht C, van Hoof A, Kluin-Nelemans HC, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008;111:558–65.

CAS  PubMed  Article  Google Scholar 

Hoster E, Rosenwald A, Berger F, Bernd H-W, Hartmann S, Loddenkemper C, et al. Prognostic value of Ki-67 index, cytology, and growth pattern in mantle-cell lymphoma: results from randomized trials of the european mantle cell lymphoma network. J Clin Oncol Off J Am Soc Clin Oncol. 2016;34:1386–94.

CAS  Article  Google Scholar 

Halldórsdóttir AM, Lundin A, Murray F, Mansouri L, Knuutila S, Sundström C, et al. Impact of TP53 mutation and 17p deletion in mantle cell lymphoma. Leukemia. 2011;25:1904–8.

PubMed  Article  Google Scholar 

Rule S, Dreyling M, Goy A, Hess G, Auer R, Kahl B, et al. Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis. Haematologica. 2019;104:e211–4.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Eskelund CW, Dahl C, Hansen JW, Westman M, Kolstad A, Pedersen LB, et al. TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. Blood. 2017;130:1903–10.

CAS  PubMed  Article  Google Scholar 

Greenwell IB, Staton AD, Lee MJ, Switchenko JM, Saxe DF, Maly JJ, et al. Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy. Cancer. 2018;124:2306–15.

PubMed  Article  Google Scholar 

Visco C, Di Rocco A, Evangelista A, Quaglia FM, Tisi MC, Morello L, et al. Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study. Leukemia. 2021;35:787–95.

CAS  PubMed  Article  Google Scholar 

Visco C, Tisi MC, Evangelista A, Di Rocco A, Zoellner A-K, Zilioli VR, et al. Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death. Br J Haematol. 2019;185:940–4.

PubMed  Article  Google Scholar 

Rampotas A, Wilson MR, Lomas O, Denny N, Leary H, Ferguson G, et al. Treatment patterns and outcomes of unfit and elderly patients with Mantle cell lymphoma unfit for standard immunochemotherapy: A UK and Ireland analysis. Br J Haematol. 2021;194:365–77.

CAS  PubMed  Article  Google Scholar 

Dreyling M, Lenz G, Hoster E, Van Hoof A, Gisselbrecht C, Schmits R, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood. 2005;105:2677–84.

CAS  PubMed  Article  Google Scholar 

Zoellner A-K, Unterhalt M, Stilgenbauer S, Hübel K, Thieblemont C, Metzner B, et al. Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial. Lancet Haematol. 2021;8:e648–57.

PubMed  Article  Google Scholar 

Geisler CH, Kolstad A, Laurell A, Jerkeman M, Räty R, Andersen NS, et al. Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur. Br J Haematol. 2012;158:355–62.

CAS  PubMed  Article  Google Scholar 

Sawalha Y, Radivoyevitch T, Jia X, Tullio K, Dean RM, Pohlman B, et al. The impact of socioeconomic disparities on the use of upfront autologous stem cell transplantation for mantle cell lymphoma. Leuk Lymphoma. 2022;63:335–43.

PubMed  Article  Google Scholar 

Merryman RW, Edwin N, Redd R, Bsat J, Chase M, LaCasce A, et al. Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma. Blood Adv. 2020;4:858–67.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Ladetto M, Cortelazzo S, Ferrero S, Evangelista A, Mian M, Tavarozzi R, et al. Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trial. Lancet Haematol. 2021;8:e34–44.

PubMed  Article  Google Scholar 

Tilch M-K, Visco C, Kinda S, Hermine O, Kohn M, Besson C, et al. Outcome of COVID-19 in patients with mantle cell lymphoma-report from the European MCL Registry. HemaSphere. 2022;6:e0711.

PubMed  PubMed Central  Article  Google Scholar 

Roeker LE, Knorr DA, Thompson MC, Nivar M, Lebowitz S, Peters N, et al. COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia. Leukemia. 2021;35:2703–5.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Herishanu Y, Avivi I, Aharon A, Shefer G, Levi S, Bronstein Y, et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood. 2021;137:3165–73.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Messmer M, Wagner-Johnston N. COVID-19 vaccination in patients on rituximab: a survey of lymphoma physicians at NCI designated cancer centers. Leuk Lymphoma. 2021;62:3019–22.

CAS  PubMed  Article  Google Scholar 

Eskelund CW, Kolstad A, Jerkeman M, Räty R, Laurell A, Eloranta S, et al. 15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau. Br J Haematol. 2016;175:410–8.

CAS  PubMed  Article  Google Scholar 

Kolstad A, Pedersen LB, Eskelund CW, Husby S, Grønbæk K, Jerkeman M, et al. Molecular monitoring after autologous stem cell transplantation and preemptive rituximab treatment of molecular relapse; results from the nordic mantle cell lymphoma studies (MCL2 and MCL3) with median follow-up of 8.5 years. Biol Blood Marrow Transplant 2017;23:428–35.

CAS  PubMed  Article  Google Scholar 

Bond DA, Switchenko JM, Villa D, Maddocks K, Churnetski M, Gerrie AS, et al. Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy. Blood Adv. 2021;5:5179–89.

PubMed  PubMed Central  Article  Google Scholar 

Munshi PN, Hamadani M, Kumar A, Dreger P, Friedberg JW, Dreyling M, et al. ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma. Bone Marrow Transplant. 2021;56:2911–21.

PubMed  PubMed Central  Article  Google Scholar 

Myers RM, Hill BT, Shaw BE, Kim S, Millard HR, Battiwalla M, et al. Long-term outcomes among 2-year survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large b-cell lymphoma. Cancer. 2018;124:816–25.

CAS  PubMed  Article  Google Scholar 

Khouri IF, Lee M-S, Saliba RM, Jun G, Fayad L, Younes A, et al. Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma. J Clin Oncol Off J Am Soc Clin Oncol. 2003;21:4407–12.

CAS  Article  Google Scholar 

Maris MB, Sandmaier BM, Storer BE, Chauncey T, Stuart MJ, Maziarz RT, et al. Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood. 2004;104:3535–42.

CAS  PubMed  Article  Google Scholar 

Krüger WH, Hirt C, Basara N, Sayer HG, Behre G, Fischer T, et al. Allogeneic stem cell transplantation for mantle cell lymphoma--final report from the prospective trials of the East German Study Group Haematology/Oncology (OSHO). Ann Hematol. 2014;93:1587–97.

PubMed  Article  Google Scholar 

Rule S, Cook G, Russell NH, Hunter A, Robinson S, Morley N, et al. Allogeneic stem cell transplantation as part of front line therapy for Mantle cell lymphoma. Br J Haematol. 2019;184:999–1005.

CAS  PubMed  Article  Google Scholar 

Hamadani M, Saber W, Ahn KW, Carreras J, Cairo MS, Fenske TS, et al. Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the center for international blood and marrow transplant research. Biol Blood Marrow Transplant 2013;19:625–31.

PubMed  PubMed Central  Article  Google Scholar 

Kharfan-Dabaja MA, Reljic T, El-Asmar J, Nishihori T, Ayala E, Hamadani M, et al. Reduced-intensity or myeloablative allogeneic hematopoietic cell transplantation for mantle cell lymphoma: a systematic review. Future Oncol Lond Engl. 2016;12:2631–42.

CAS  Article  Google Scholar 

Marangon M, Visco C, Barbui AM, Chiappella A, Fabbri A, Ferrero S, et al. Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma in the Era of New Drugs and CAR-T Cell Therapy. Cancers. 2021;13:291.

CAS  PubMed  PubMed Central  Article